Short Communication - Archives of Industrial Biotechnology (2023) Volume 7, Issue 3
Genome Editing in Industrial Biotechnology: CRISPR-Cas9 and Beyond
Joeva Sean Stone*
Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, North Carolina, USA
- Corresponding Author:
- Joeva Sean Stone
Department of Food
Bioprocessing and Nutrition Sciences
North Carolina State University
North Carolina, USA
Email id: firstname.lastname@example.org
Received: 29-May-2023, Manuscript No. AAAIB-23-109064; Editor assigned: 01-Jun-2023, PreQC No. AAAIB-23-109064(PQ); Reviewed: 15-Jun-2023, QC No. AAAIB-23-109064; Revised: 17-Jun-2023, Manuscript No. AAAIB-23-109064(R); Published: 24-Jun-2023, DOI:10.35841/aaaib-7.3.151
Citation: Stone JS. Genome editing in industrial biotechnology: CRISPR-Cas9 and beyond. J Arch Ind Biot. 2023;7(3):151
The field of industrial biotechnology has witnessed revolutionary advancements in recent years, largely due to the emergence of powerful genome editing technologies. Among these, CRISPR-Cas9 has emerged as a gamechanger, enabling precise and efficient modifications of genetic material. The ability to edit genomes with such precision has opened up exciting new possibilities in various industries, from agriculture and pharmaceuticals to biofuels and biomanufacturing. In this article, we will explore the role of CRISPR-Cas9 in industrial biotechnology and delve into the promising prospects of genome editing beyond CRISPRCas9.
CRISPR-Cas9: A breakthrough in genome editing
CRISPR-Cas9, short for Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated protein 9, is a revolutionary genome editing tool. It originated from the bacterial immune system, where it serves as a defense mechanism against viral infections. The system consists of two main components: the CRISPR RNA (crRNA) that guides the system to its target DNA sequence, and the Cas9 protein, which acts as a molecular pair of scissors, cutting the DNA at the desired location. The versatility of CRISPR-Cas9 lies in its ability to be programmed to target specific DNA sequences within the genome of virtually any organism. By introducing custom-designed crRNA, researchers can guide the Cas9 protein to specific genes and induce changes such as gene knockout, gene insertion, or precise gene editing. The simplicity, cost-effectiveness, and efficiency of CRISPR-Cas9 have revolutionized genome editing, opening up a wide range of applications in industrial biotechnology .
Applications of CRISPR-Cas9 in industrial biotechnology
CRISPR-Cas9 has tremendous potential in crop improvement. By editing the genes responsible for specific traits, such as disease resistance, drought tolerance, and improved nutritional content, scientists can develop crops with enhanced productivity and sustainability. Additionally, CRISPR-Cas9 can aid in reducing the need for harmful pesticides and herbicides, promoting environmentally friendly agriculture. Genome editing using CRISPR-Cas9 has revolutionized drug development. It enables researchers to create accurate disease models, allowing for a deeper understanding of diseases and the development of more effective therapies. CRISPR-Cas9 can also be employed to engineer cell lines for biopharmaceutical production, streamlining the production of therapeutic proteins. Industrial biotechnology is driving the development of sustainable biofuels. CRISPR-Cas9 can be used to modify the metabolic pathways of microorganisms, enhancing their ability to produce biofuels from renewable feedstocks efficiently .
Industrial enzyme productions are enzymes play a vital role in various industrial processes, from detergents and textiles to biofuels and pharmaceuticals. CRISPR-Cas9 can be utilized to improve enzyme production in microbial hosts, leading to more cost-effective and eco-friendly processes .
Beyond CRISPR-Cas9: Emerging genome editing technologies
While CRISPR-Cas9 has undoubtedly been a ground breaking technology, ongoing research continues to explore and refine other genome editing tools.
CRISPR-Cas12 and Cas13 systems work similarly to CRISPRCas9 but use different cas proteins. CRISPR-Cas12 offers additional targeting capabilities, while Cas13 allows for RNA editing, expanding the scope of genome editing applications.
Base editors enable precise changes to single DNA bases without introducing double-strand breaks. This technology is particularly promising for correcting point mutations associated with genetic diseases.
Prime editing is a recent development that combines CRISPRCas9 with a reverse transcriptase enzyme. It allows for the precise addition, deletion, or modification of DNA sequences, offering greater flexibility in genome editing.
Epigenome editing is used while not altering the DNA sequence itself, epigenome editing can modify the chemical modifications of DNA or histone proteins, influencing gene expression without permanently changing the genetic code .
Ethical and regulatory considerations
The remarkable potential of genome editing technologies, including CRISPR-Cas9 and its successors, raises important ethical and regulatory questions. One of the primary concerns is the use of genome editing in human embryos or germline cells, as any alterations made could be passed down to future generations. Striking a balance between advancing scientific knowledge and ensuring responsible use of these technologies is crucial to avoid potential unintended consequences. Moreover, concerns about unintended off-target effects and the potential for creating Genetically Modified Organisms (GMOs) with unpredictable ecological impacts necessitate strict regulatory oversight .
Genome editing, led by CRISPR-Cas9 and its expanding toolkit, has revolutionized the landscape of industrial biotechnology. The ability to precisely modify genetic material has opened up endless possibilities for sustainable agriculture, drug development, biofuel production, and various other industries. However, with such advancements come ethical and regulatory challenges that must be navigated carefully. As research continues and new genome editing technologies emerge, the future of industrial biotechnology holds immense promise. With responsible and innovative use, these technologies can drive unprecedented progress in addressing global challenges while ushering in a new era of sustainable, precise, and environmentally friendly industrial practices.
- Brinegar K, Yetisen A, Choi S, et al. The commercialization of genome-editing technologies. Crit Rev Biotechnol. 2017;37(7):924-32.
- Chen K, Wang Y, Zhang R, et al. CRISPR/Cas genome editing and precision plant breeding in agriculture. Annu Rev Plant Biol. 2019;70:667-97.
- Dale PJ. Public reactions and scientific responses to transgenic crops: Commentary. Curr Opin Biotechnol. 1999;10(2):203-8.
- Egelie KJ, Graff GD, Strand SP, et al. The emerging patent landscape of CRISPR–Cas gene editing technology. Nat biotechnol. 2016;34(10):1025-31.
- Gao C. Genome engineering for crop improvement and future agriculture. Cell. 2021;184(6):1621-35.